{"success":true,"data":{"pressRelease":{"id":"155240","rtpr_id":"nGNX68V3C6-20260929","ticker":"VCYT","exchange":"NASDAQ","all_tickers":["VCYT"],"title":"Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation","author":"Globe Newswire","published_at":"2026-09-29T12:00:02.498Z","article_body":"SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc.\n(Nasdaq: VCYT), a leading cancer diagnostics company, announced that new\nfindings from a retrospective ancillary analysis of the randomized phase III\nNRG/RTOG 0815 trial will be presented at the 2026 American Society for\nRadiation Oncology (ASTRO) Annual Meeting. The trial evaluated dose-escalated\nradiation with or without short-term androgen deprivation therapy (ADT) in men\nwith intermediate-risk prostate cancer. The analysis showed that the Decipher\nProstate Genomic Classifier can predict which patients are more likely to\nbenefit from adding short-term ADT to dose-escalated radiation, providing both\nLevel 1B(1) prognostic and predictive evidence.\n\nIn the study, patients with higher Decipher scores had substantially improved\noutcomes with the addition of short-term ADT to radiation, while patients with\nlow Decipher scores derived minimal treatment benefit. These findings extend\nDecipher’s long-established role in assessing the risk of prostate cancer\nprogression to informing treatment selection for patients with\nintermediate-risk disease. The results will be presented today at 3:55 p.m. ET\nin an oral session at the 2026 ASTRO Annual Meeting by Angela Jia, M.D.,\nPh.D., University Hospitals Seidman Cancer Center, Case Western Reserve\nUniversity.\n\n“For men with intermediate-risk prostate cancer, the question is not simply\nwhether hormone therapy works — it is who truly needs it,” said Angela\nJia, M.D., Ph.D. “This analysis suggests tumor biology can distinguish\npatients who may achieve a substantial reduction in the risk of distant\nmetastasis from those who may see little added benefit. That could help\nclinicians and patients make a more individualized decision about intensifying\ntreatment.”\n\nWhile ADT can reduce the risk of recurrence and distant spread, it can also\nhave metabolic and quality-of-life effects. Because intermediate-risk disease\nis biologically diverse, clinical variables such as Gleason grade, PSA or\nclinical stage may not reveal which patients are most likely to benefit from\nadding the therapy.\n\nKey study findings:\n* Decipher predicted differential benefit from hormone therapy: The\ntreatment-by-Decipher interaction for distant metastasis was statistically\nsignificant (p<0.001).\n* Patients with higher scores experienced substantially greater benefit: Among\npatients with intermediate/high Decipher scores, adding short-term ADT was\nassociated with an 8% absolute reduction in distant metastasis at 10 years.\n* Patients with low scores did not have substantial benefit from short-term\nADT: Among the 44% of patients with low Decipher scores, the absolute\ndifference in 10-year distant metastasis was 1 percentage point and was not\nstatistically significant.\nDecipher also refined prognosis: Higher scores were independently associated\nwith greater risk of biochemical failure, distant metastasis and\nprostate-specific mortality. Researchers analyzed tumor samples from 395\npatients enrolled in NRG/RTOG 0815, with a median follow up of 10.2 years. The\nbiomarker cohort was representative of the overall trial enrollment of 1,492\npatients and was balanced between treatment arms. The Decipher score was both\nprognostic for disease outcomes and predictive of ADT benefit for both distant\nmetastasis as well as prostate cancer specific mortality endpoints.\n\n“For men with intermediate-risk prostate cancer, these findings provide\npredictive evidence that treatment decisions can be guided by the biology of\neach patient's tumor, not simply a broad clinical risk category,” said\nDaniel E. Spratt, M.D., chair of the Department of Radiation Oncology at\nUniversity Hospitals Cleveland Medical Center, professor at Case Western\nReserve University School of Medicine, and a study author. “Decipher may\nhelp identify who is likely to gain meaningful protection from metastasis by\nadding hormone therapy and who may face its health and quality-of-life effects\nwith little added benefit. That is the kind of precision that patients and\nphysicians need when deciding how aggressively to treat the cancer.”\n\n“These findings provide the first evidence that Decipher can predict which\nmen with intermediate-risk prostate cancer are most likely to benefit from\nadding hormone therapy to radiation,” said Elai Davicioni, Ph.D.,\nVeracyte’s medical director, Urology. “This extends the Decipher test’s\nprognostic use toward answering a more consequential question: Will this\ntreatment make a meaningful difference for this patient? By revealing the\nbiology beneath a broad clinical risk category, Decipher may help physicians\nintensify treatment for patients most likely to benefit while potentially\nsparing others from side effects with little added benefit. With the addition\nof these findings, we believe that all men diagnosed with intermediate-risk\nprostate cancer may benefit from the use of Decipher in their care pathway.”\n\nASTRO 2026 presentation details\n\nAbstract #312: Genomic Stratification of Benefit from Short-Term Androgen\nDeprivation with Dose-Escalated Radiotherapy in Intermediate-Risk Prostate\nCancer: An Ancillary Study of NRG/RTOG 0815\n* Session: SS 36 - Predicting Benefit and Toxicity: Biomarkers in Prostate\nRadiotherapy\n* Presenter: Angela Jia, M.D., Ph.D.\n* Date and time: Tuesday, September 29, 2026, 3:55–4:05 p.m. ET\n* Location: Room 210, Thomas M. Menino Convention & Exhibition Center, Boston\nAnother trial prospectively evaluating the use of the Decipher prostate test\nto guide treatment intensification or de-intensification is the phase III\nbiomarker-driven NRG-GU010 (GUIDANCE) study, which completed enrollment\nearlier this year. This trial will build on the findings from the NRG/RTOG\n0815 trial, further expanding the predictive evidence around the Decipher test\nin intermediate-risk disease.\n\nAbout the NRG/RTOG 0815 analysis\n\nNRG/RTOG 0815 was a randomized phase III trial evaluating the addition of\nshort-term ADT to dose-escalated radiation in patients with intermediate-risk\nprostate cancer. In this NCI-approved ancillary analysis, archived diagnostic\nbiopsy specimens were evaluated using the locked, clinical-grade 22-gene\nDecipher Genomic Classifier. The analysis included 395 patients with a median\nfollow-up of 10.2 years. The primary endpoint was distant metastasis;\nsecondary endpoints included biochemical failure, metastasis-free survival,\nprostate cancer-specific mortality and overall survival.\n\nAbout Veracyte\n\nVeracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to\ntransform cancer care for patients around the world. The company’s\nmolecular tests assess the unique biology of each patient’s tumor to help\nclinicians answer essential questions about cancer care. Veracyte’s\nDiagnostics Platform\n(https://www.globenewswire.com/Tracker?data=yQHmSqE4fxL10-4p09GMQ1HhSm5dSTKXO4Yqxme5bsDG3FMiyXMVWfFwJoMIZ6djOex23R9UmbtZyyFd7DNy2k41w9wyfldwCuz76Oa9NJo-x0FTyCqlpSgbcT_Kf3ndc8YPjMmVH1hAOhkhGC4Yw32MoBLf1YS6PBGjJy3_22E=) combines\nbroad genomic and clinical data, advanced bioinformatics and AI, and\na powerful evidence-generation engine to support continued innovation\nand pipeline development\n(https://www.globenewswire.com/Tracker?data=LrcfiSUSgqaL2SGkxm_7nqP4j7eO3Nwi9yNEo3EdeaLG02NlnTRKEw_6NC5bme6JL4XGFdazC2Jl2-3aU2abS9v2x3jgXy7LKzeczugjagDLzU4Suv4G5X82rZRQeIGVXHgNhswRfYcaM2kWNKAk9lniZiunfEJgAqNw0ZYiF-s=).\nThe company’s portfolio includes the Afirma® Genomic Sequencing\nClassifier test\n(https://www.globenewswire.com/Tracker?data=2o7Wjk2MCpn5UnbzxXpKWQgbLTxf1BZNmITAjGtjHjggfDFU6Nc0Jh5ABL31iXyOqv5lFNq9InEjSbQCIIyRwpv-NQhKNJAoZbbDWAVj4mt_5a3K_G5RyzavDNNpOFzNkDyz-6IlF-kKVnZoLoFxdyhLMSzT_ZT2h4d10Dw8P84=), Decipher®\nBladder Genomic Classifier test\n(https://www.globenewswire.com/Tracker?data=wS7pKPpgS9gkWHlfjardSGWzBXmTNaUg0uO9rOrHGIqv8rlQt0a-KK53FXTnqOUIk9iqMHiuP-yuBVBgLOTkJdtptKLWlTM7XaIwM4RbGxhsr_mmVWzJhAtUPHVgCLmMfTejzBSzc8eNSZrdCmJcQ_GtHUwb1tIJ2zqytmfwADI=), Decipher®\nProstate Genomic Classifier test\n(https://www.globenewswire.com/Tracker?data=wS7pKPpgS9gkWHlfjardSAke68r9p1cMYX-cEHE6HWY3xJte4GBNHqhnjzG-K6387U6jDJfeqagjDBREE60dEtmW_hB5DVhms80pI5DTEbyMJ7_W8eCsfgDAmJh6RQWJNi0JsWM7LeywIKWt9AU3P3F6ABG_9LSohR-S9S7IFU8=), Prosigna®\nBreast Risk of Recurrence test\n(https://www.globenewswire.com/Tracker?data=zNmBJozewodrC1j4U1QmvfkudbDZFbf778aPGm_lG4lTzVUoC8CXpKU1cJN4RY9PRy8l97njZ05wmYTHKoOips54-bHcH9Ey732wPHOW6XPIsG3A9rGhIAVZIKobGY9f4F4GZ-Bkty-SRDURZmldNA==),\nand the TrueMRD™ Monitoring Test for MIBC\n(https://www.globenewswire.com/Tracker?data=ao1LQ7j5IglVZQvLqMG1Qnh51K9CGc8QLrez0_W9A9ZpYYBViCJwb0qmMuylHzysDCO6y2zBvf6E_k0zh8YEYQ-8n76CXgIPUfM5rEyc5v0d642bSYobGpQgDPyyJ8uusmqzyc13KZJt3nU8NKBVRg==). For\nmore information, visit Veracyte’s website\n(https://www.globenewswire.com/Tracker?data=PjpTJftzzeaICuIG7ir5XKweMavAD02r67VXqYRGaDLE1ItkT8VSdS4ngvZMnsgyCt6v2c9DNo8qWiC44P7M_Q==) or\nfollow the company on LinkedIn\n(https://www.globenewswire.com/Tracker?data=VmMJt8tF14fjgljAUpX4ZmwehEx9tyr36Mye0Q1CbOympUb8VOphqBjPKPEpQAgU2hMeQ0QXlFe4kQtSGeF_EZHL17bjPqazUMyprbb98yw=) or X\n(Twitter)\n(https://www.globenewswire.com/Tracker?data=DCdQheLtFTPUZik-CiFDAgBud3zIrzHbTkmmmkxb_9itTXjTZmKM4mAHA7rqGIZpr3FJjSavKyp_FR2lV2xgXg==).  \n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements, including, but not\nlimited to statements regarding the potential clinical utility, impact and\nbenefits of the Decipher Prostate Genomic Classifier; the ability of the\nDecipher Prostate test to predict which patients with intermediate-risk\nprostate cancer may benefit from the addition of short-term ADT; the potential\nuse of Decipher to inform treatment selection and personalize treatment\ndecisions; the potential for Decipher to expand beyond risk assessment to\nguide treatment decisions in intermediate-risk prostate cancer; and the\nsignificance and clinical implications of the study findings, and the\npotential outcomes, validation and impact of the ongoing NRG-GU010 GUIDANCE\nclinical trial. Forward-looking statements can be identified by words such as\n“appears,” “anticipate,” “intend,” “plan,” “expect,”\n“believe,” “should,” “may,” “will,” “enable,”\n“positioned,” “offers,” “designed,” “ultimately,” and similar\nreferences to future periods. Actual results may differ materially from those\nprojected or suggested in any forward-looking statements. These statements\ninvolve risks and uncertainties, which could cause actual results to differ\nmaterially from our predictions. Additional factors that may impact these\nforward-looking statements can be found under the caption 'Risk Factors' in\nour Annual Report on Form 10-K filed on February 26, 2026, as well as in other\ndocuments that we may file from time to time with the Securities and Exchange\nCommission. Copies of these documents, when available, may be found in the\nInvestors section of our website at investor.veracyte.com. These\nforward-looking statements speak only as of the date hereof and, except as\nrequired by law, we specifically disclaim any obligation to update these\nforward-looking statements or reasons why actual results might differ, whether\nas a result of new information, future events or otherwise.\n\nReferences:\n1. Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in\nevaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101,\n1446–1452 (2009). https://doi.org/10.1093/jnci/djp335\nInvestors: \nKelly Gura  \ninvestors@veracyte.com\n\nMedia: \nMolly Cornbleet \nmedia@veracyte.com \n+1 650-351-8780\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cd03c874-765a-4f63-85f9-9438bda7775f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX68V3C6-20260929","title":"Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation","author":"Globe Newswire","ticker":"VCYT","created":"2026-09-29T12:00:02.498Z","tickers":["VCYT"],"exchange":"NASDAQ","article_body":"SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc.\n(Nasdaq: VCYT), a leading cancer diagnostics company, announced that new\nfindings from a retrospective ancillary analysis of the randomized phase III\nNRG/RTOG 0815 trial will be presented at the 2026 American Society for\nRadiation Oncology (ASTRO) Annual Meeting. The trial evaluated dose-escalated\nradiation with or without short-term androgen deprivation therapy (ADT) in men\nwith intermediate-risk prostate cancer. The analysis showed that the Decipher\nProstate Genomic Classifier can predict which patients are more likely to\nbenefit from adding short-term ADT to dose-escalated radiation, providing both\nLevel 1B(1) prognostic and predictive evidence.\n\nIn the study, patients with higher Decipher scores had substantially improved\noutcomes with the addition of short-term ADT to radiation, while patients with\nlow Decipher scores derived minimal treatment benefit. These findings extend\nDecipher’s long-established role in assessing the risk of prostate cancer\nprogression to informing treatment selection for patients with\nintermediate-risk disease. The results will be presented today at 3:55 p.m. ET\nin an oral session at the 2026 ASTRO Annual Meeting by Angela Jia, M.D.,\nPh.D., University Hospitals Seidman Cancer Center, Case Western Reserve\nUniversity.\n\n“For men with intermediate-risk prostate cancer, the question is not simply\nwhether hormone therapy works — it is who truly needs it,” said Angela\nJia, M.D., Ph.D. “This analysis suggests tumor biology can distinguish\npatients who may achieve a substantial reduction in the risk of distant\nmetastasis from those who may see little added benefit. That could help\nclinicians and patients make a more individualized decision about intensifying\ntreatment.”\n\nWhile ADT can reduce the risk of recurrence and distant spread, it can also\nhave metabolic and quality-of-life effects. Because intermediate-risk disease\nis biologically diverse, clinical variables such as Gleason grade, PSA or\nclinical stage may not reveal which patients are most likely to benefit from\nadding the therapy.\n\nKey study findings:\n* Decipher predicted differential benefit from hormone therapy: The\ntreatment-by-Decipher interaction for distant metastasis was statistically\nsignificant (p<0.001).\n* Patients with higher scores experienced substantially greater benefit: Among\npatients with intermediate/high Decipher scores, adding short-term ADT was\nassociated with an 8% absolute reduction in distant metastasis at 10 years.\n* Patients with low scores did not have substantial benefit from short-term\nADT: Among the 44% of patients with low Decipher scores, the absolute\ndifference in 10-year distant metastasis was 1 percentage point and was not\nstatistically significant.\nDecipher also refined prognosis: Higher scores were independently associated\nwith greater risk of biochemical failure, distant metastasis and\nprostate-specific mortality. Researchers analyzed tumor samples from 395\npatients enrolled in NRG/RTOG 0815, with a median follow up of 10.2 years. The\nbiomarker cohort was representative of the overall trial enrollment of 1,492\npatients and was balanced between treatment arms. The Decipher score was both\nprognostic for disease outcomes and predictive of ADT benefit for both distant\nmetastasis as well as prostate cancer specific mortality endpoints.\n\n“For men with intermediate-risk prostate cancer, these findings provide\npredictive evidence that treatment decisions can be guided by the biology of\neach patient's tumor, not simply a broad clinical risk category,” said\nDaniel E. Spratt, M.D., chair of the Department of Radiation Oncology at\nUniversity Hospitals Cleveland Medical Center, professor at Case Western\nReserve University School of Medicine, and a study author. “Decipher may\nhelp identify who is likely to gain meaningful protection from metastasis by\nadding hormone therapy and who may face its health and quality-of-life effects\nwith little added benefit. That is the kind of precision that patients and\nphysicians need when deciding how aggressively to treat the cancer.”\n\n“These findings provide the first evidence that Decipher can predict which\nmen with intermediate-risk prostate cancer are most likely to benefit from\nadding hormone therapy to radiation,” said Elai Davicioni, Ph.D.,\nVeracyte’s medical director, Urology. “This extends the Decipher test’s\nprognostic use toward answering a more consequential question: Will this\ntreatment make a meaningful difference for this patient? By revealing the\nbiology beneath a broad clinical risk category, Decipher may help physicians\nintensify treatment for patients most likely to benefit while potentially\nsparing others from side effects with little added benefit. With the addition\nof these findings, we believe that all men diagnosed with intermediate-risk\nprostate cancer may benefit from the use of Decipher in their care pathway.”\n\nASTRO 2026 presentation details\n\nAbstract #312: Genomic Stratification of Benefit from Short-Term Androgen\nDeprivation with Dose-Escalated Radiotherapy in Intermediate-Risk Prostate\nCancer: An Ancillary Study of NRG/RTOG 0815\n* Session: SS 36 - Predicting Benefit and Toxicity: Biomarkers in Prostate\nRadiotherapy\n* Presenter: Angela Jia, M.D., Ph.D.\n* Date and time: Tuesday, September 29, 2026, 3:55–4:05 p.m. ET\n* Location: Room 210, Thomas M. Menino Convention & Exhibition Center, Boston\nAnother trial prospectively evaluating the use of the Decipher prostate test\nto guide treatment intensification or de-intensification is the phase III\nbiomarker-driven NRG-GU010 (GUIDANCE) study, which completed enrollment\nearlier this year. This trial will build on the findings from the NRG/RTOG\n0815 trial, further expanding the predictive evidence around the Decipher test\nin intermediate-risk disease.\n\nAbout the NRG/RTOG 0815 analysis\n\nNRG/RTOG 0815 was a randomized phase III trial evaluating the addition of\nshort-term ADT to dose-escalated radiation in patients with intermediate-risk\nprostate cancer. In this NCI-approved ancillary analysis, archived diagnostic\nbiopsy specimens were evaluated using the locked, clinical-grade 22-gene\nDecipher Genomic Classifier. The analysis included 395 patients with a median\nfollow-up of 10.2 years. The primary endpoint was distant metastasis;\nsecondary endpoints included biochemical failure, metastasis-free survival,\nprostate cancer-specific mortality and overall survival.\n\nAbout Veracyte\n\nVeracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to\ntransform cancer care for patients around the world. The company’s\nmolecular tests assess the unique biology of each patient’s tumor to help\nclinicians answer essential questions about cancer care. Veracyte’s\nDiagnostics Platform\n(https://www.globenewswire.com/Tracker?data=yQHmSqE4fxL10-4p09GMQ1HhSm5dSTKXO4Yqxme5bsDG3FMiyXMVWfFwJoMIZ6djOex23R9UmbtZyyFd7DNy2k41w9wyfldwCuz76Oa9NJo-x0FTyCqlpSgbcT_Kf3ndc8YPjMmVH1hAOhkhGC4Yw32MoBLf1YS6PBGjJy3_22E=) combines\nbroad genomic and clinical data, advanced bioinformatics and AI, and\na powerful evidence-generation engine to support continued innovation\nand pipeline development\n(https://www.globenewswire.com/Tracker?data=LrcfiSUSgqaL2SGkxm_7nqP4j7eO3Nwi9yNEo3EdeaLG02NlnTRKEw_6NC5bme6JL4XGFdazC2Jl2-3aU2abS9v2x3jgXy7LKzeczugjagDLzU4Suv4G5X82rZRQeIGVXHgNhswRfYcaM2kWNKAk9lniZiunfEJgAqNw0ZYiF-s=).\nThe company’s portfolio includes the Afirma® Genomic Sequencing\nClassifier test\n(https://www.globenewswire.com/Tracker?data=2o7Wjk2MCpn5UnbzxXpKWQgbLTxf1BZNmITAjGtjHjggfDFU6Nc0Jh5ABL31iXyOqv5lFNq9InEjSbQCIIyRwpv-NQhKNJAoZbbDWAVj4mt_5a3K_G5RyzavDNNpOFzNkDyz-6IlF-kKVnZoLoFxdyhLMSzT_ZT2h4d10Dw8P84=), Decipher®\nBladder Genomic Classifier test\n(https://www.globenewswire.com/Tracker?data=wS7pKPpgS9gkWHlfjardSGWzBXmTNaUg0uO9rOrHGIqv8rlQt0a-KK53FXTnqOUIk9iqMHiuP-yuBVBgLOTkJdtptKLWlTM7XaIwM4RbGxhsr_mmVWzJhAtUPHVgCLmMfTejzBSzc8eNSZrdCmJcQ_GtHUwb1tIJ2zqytmfwADI=), Decipher®\nProstate Genomic Classifier test\n(https://www.globenewswire.com/Tracker?data=wS7pKPpgS9gkWHlfjardSAke68r9p1cMYX-cEHE6HWY3xJte4GBNHqhnjzG-K6387U6jDJfeqagjDBREE60dEtmW_hB5DVhms80pI5DTEbyMJ7_W8eCsfgDAmJh6RQWJNi0JsWM7LeywIKWt9AU3P3F6ABG_9LSohR-S9S7IFU8=), Prosigna®\nBreast Risk of Recurrence test\n(https://www.globenewswire.com/Tracker?data=zNmBJozewodrC1j4U1QmvfkudbDZFbf778aPGm_lG4lTzVUoC8CXpKU1cJN4RY9PRy8l97njZ05wmYTHKoOips54-bHcH9Ey732wPHOW6XPIsG3A9rGhIAVZIKobGY9f4F4GZ-Bkty-SRDURZmldNA==),\nand the TrueMRD™ Monitoring Test for MIBC\n(https://www.globenewswire.com/Tracker?data=ao1LQ7j5IglVZQvLqMG1Qnh51K9CGc8QLrez0_W9A9ZpYYBViCJwb0qmMuylHzysDCO6y2zBvf6E_k0zh8YEYQ-8n76CXgIPUfM5rEyc5v0d642bSYobGpQgDPyyJ8uusmqzyc13KZJt3nU8NKBVRg==). For\nmore information, visit Veracyte’s website\n(https://www.globenewswire.com/Tracker?data=PjpTJftzzeaICuIG7ir5XKweMavAD02r67VXqYRGaDLE1ItkT8VSdS4ngvZMnsgyCt6v2c9DNo8qWiC44P7M_Q==) or\nfollow the company on LinkedIn\n(https://www.globenewswire.com/Tracker?data=VmMJt8tF14fjgljAUpX4ZmwehEx9tyr36Mye0Q1CbOympUb8VOphqBjPKPEpQAgU2hMeQ0QXlFe4kQtSGeF_EZHL17bjPqazUMyprbb98yw=) or X\n(Twitter)\n(https://www.globenewswire.com/Tracker?data=DCdQheLtFTPUZik-CiFDAgBud3zIrzHbTkmmmkxb_9itTXjTZmKM4mAHA7rqGIZpr3FJjSavKyp_FR2lV2xgXg==).  \n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements, including, but not\nlimited to statements regarding the potential clinical utility, impact and\nbenefits of the Decipher Prostate Genomic Classifier; the ability of the\nDecipher Prostate test to predict which patients with intermediate-risk\nprostate cancer may benefit from the addition of short-term ADT; the potential\nuse of Decipher to inform treatment selection and personalize treatment\ndecisions; the potential for Decipher to expand beyond risk assessment to\nguide treatment decisions in intermediate-risk prostate cancer; and the\nsignificance and clinical implications of the study findings, and the\npotential outcomes, validation and impact of the ongoing NRG-GU010 GUIDANCE\nclinical trial. Forward-looking statements can be identified by words such as\n“appears,” “anticipate,” “intend,” “plan,” “expect,”\n“believe,” “should,” “may,” “will,” “enable,”\n“positioned,” “offers,” “designed,” “ultimately,” and similar\nreferences to future periods. Actual results may differ materially from those\nprojected or suggested in any forward-looking statements. These statements\ninvolve risks and uncertainties, which could cause actual results to differ\nmaterially from our predictions. Additional factors that may impact these\nforward-looking statements can be found under the caption 'Risk Factors' in\nour Annual Report on Form 10-K filed on February 26, 2026, as well as in other\ndocuments that we may file from time to time with the Securities and Exchange\nCommission. Copies of these documents, when available, may be found in the\nInvestors section of our website at investor.veracyte.com. These\nforward-looking statements speak only as of the date hereof and, except as\nrequired by law, we specifically disclaim any obligation to update these\nforward-looking statements or reasons why actual results might differ, whether\nas a result of new information, future events or otherwise.\n\nReferences:\n1. Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in\nevaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101,\n1446–1452 (2009). https://doi.org/10.1093/jnci/djp335\nInvestors: \nKelly Gura  \ninvestors@veracyte.com\n\nMedia: \nMolly Cornbleet \nmedia@veracyte.com \n+1 650-351-8780\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cd03c874-765a-4f63-85f9-9438bda7775f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T12:00:02.676465542Z","server_sent_at_ms":1790683202676},"received_at":"2026-09-29T12:00:02.729Z","source_url":null},"analysis":{"id":"143973","press_release_id":"155240","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["findings are from a retrospective ancillary analysis, not a prospective trial endpoint","clinical and commercial impact depends on guideline adoption and reimbursement, not yet confirmed"],"eventType":"clinical_trial","narrative":"Veracyte announced phase III NRG/RTOG 0815 ancillary analysis data showing the Decipher Prostate test predicts which intermediate-risk prostate cancer patients benefit from adding short-term hormone therapy to radiation, with Level 1B prognostic and predictive evidence.\n\nPatients with intermediate/high Decipher scores saw an 8% absolute reduction in 10-year distant metastasis with added ADT, while the 44% with low scores derived no statistically significant benefit.\n\nThe company says this extends Decipher from prognostic use toward treatment selection, potentially expanding the addressable population to all intermediate-risk prostate cancer patients; the prospective NRG-GU010 GUIDANCE trial has completed enrollment to build on these findings.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Predictive Level 1B evidence could broaden Decipher's use across all intermediate-risk prostate cancer patients -- a potential volume tailwind for VCYT's core urology franchise."},"keyFigures":{"drugName":"Decipher Prostate Genomic Classifier","phaseOfTrial":"Phase III","customDimensions":{"low_score_share":"44%","biomarker_cohort":395,"trial_enrollment":1492,"interaction_p_value":"p<0.001","median_follow_up_years":10.2,"absolute_difference_low_scores":"1 percentage point (not significant)","absolute_metastasis_reduction_high_scores":"8% at 10 years"}},"quotedText":"For men with intermediate-risk prostate cancer, these findings provide predictive evidence that treatment decisions can be guided by the biology of each patient's tumor, not simply a broad clinical risk category","namedEntities":{"people":[{"name":"Angela Jia, M.D., Ph.D.","role":"study presenter, University Hospitals Seidman Cancer Center"},{"name":"Daniel E. Spratt, M.D.","role":"chair, Radiation Oncology, University Hospitals Cleveland Medical Center; study author"},{"name":"Elai Davicioni, Ph.D.","role":"Veracyte medical director, Urology"}],"products":["Decipher Prostate Genomic Classifier","Afirma Genomic Sequencing Classifier","Decipher Bladder Genomic Classifier","Prosigna Breast Risk of Recurrence test","TrueMRD Monitoring Test for MIBC"],"companies":[{"name":"Veracyte, Inc.","ticker":"VCYT","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Level 1B predictive evidence from a randomized phase III trial could expand Decipher use to all intermediate-risk prostate cancer patients and support reimbursement/guideline adoption, but it is a retrospective ancillary analysis presented at a conference, not a regulatory or revenue event."},"tickerRelevance":{"others":[],"primary":"VCYT"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"positive phase III biomarker data at major conference","sectorWeight":"diagnostics","retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Veracyte announced phase III NRG/RTOG 0815 ancillary analysis data showing the Decipher Prostate test predicts which intermediate-risk prostate cancer patients benefit from adding short-term hormone therapy to radiation, with Level 1B prognostic and predictive evidence.\n\nPatients with intermediate/high Decipher scores saw an 8% absolute reduction in 10-year distant metastasis with added ADT, while the 44% with low scores derived no statistically significant benefit.\n\nThe company says this extends Decipher from prognostic use toward treatment selection, potentially expanding the addressable population to all intermediate-risk prostate cancer patients; the prospective NRG-GU010 GUIDANCE trial has completed enrollment to build on these findings.","key_figures":{"drugName":"Decipher Prostate Genomic Classifier","phaseOfTrial":"Phase III","customDimensions":{"low_score_share":"44%","biomarker_cohort":395,"trial_enrollment":1492,"interaction_p_value":"p<0.001","median_follow_up_years":10.2,"absolute_difference_low_scores":"1 percentage point (not significant)","absolute_metastasis_reduction_high_scores":"8% at 10 years"}},"named_entities":{"people":[{"name":"Angela Jia, M.D., Ph.D.","role":"study presenter, University Hospitals Seidman Cancer Center"},{"name":"Daniel E. Spratt, M.D.","role":"chair, Radiation Oncology, University Hospitals Cleveland Medical Center; study author"},{"name":"Elai Davicioni, Ph.D.","role":"Veracyte medical director, Urology"}],"products":["Decipher Prostate Genomic Classifier","Afirma Genomic Sequencing Classifier","Decipher Bladder Genomic Classifier","Prosigna Breast Risk of Recurrence test","TrueMRD Monitoring Test for MIBC"],"companies":[{"name":"Veracyte, Inc.","ticker":"VCYT","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T12:00:24.378Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"positive phase III biomarker data at major conference","sectorWeight":"diagnostics","retailFavoriteBoost":0}},"durationMs":6680,"modelName":"glm-5.3-flashx"}}